Quantum-Si Incorporated Dossier
|
SectorHealth Care IndustryLife Sciences Tools & Services Beta (adjusted)2.50 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.43Price as of 1 Oct 2026 Data confidence Sign in to view data confidence Market Cap $313M Enterprise Value $293.1M Shares Outstanding 231.9M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Quantum-Si is in a critical transition phase as it shifts focus from its first-generation Platinum protein sequencer to the upcoming Proteus platform, scheduled for commercial launch by the end of 2026. While the technology holds significant long-term potential to democratize single-molecule proteomics, near-term revenues remain minimal ($258,000 in Q1 2026) as customers defer purchases ahead of the Proteus launch. The company maintains a solid cash runway of $190.4 million, expected to fund operations into the second quarter of 2028, providing roughly 18 months of post-launch execution runway. Given the pre-revenue commercial stage and high execution risks, a Hold rating is appropriate until initial Proteus commercial traction and system validation are demonstrated. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$1.00 Mean target$2.50 High · most bullish analyst$4.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $1.0015% The commercial launch of Proteus is delayed into 2027 due to manufacturing transfer or systems integration issues. Early instruments experience technical underperformance or fail to meet customer expectations for amino acid coverage. Cash burn accelerates, forcing a highly dilutive equity raise before the platform achieves commercial viability. Base CaseCentral scenario $2.5060% Matches the consensus meanProteus launches by the end of 2026 with controlled initial adoption. Revenue for 2026 meets management's guidance of approximately $1.0 million, and 2027 sees a gradual ramp in instrument placements. The company manages its cash burn within the guided limits, preserving its runway into 2028 while proving the platform's utility in early-access sites. Bull CaseUpside scenario $4.0025% The Proteus platform launches on schedule in late 2026 with robust early adoption from academic and biopharma labs. The system successfully demonstrates detection of all 20 amino acids and post-translational modifications (PTMs), displacing expensive mass spectrometry workflows. Rapid instrument placements drive high-margin recurring consumables revenue, accelerating the path to profitability. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |